Teva’s Allergan Bid May Give Vigodman Exit From Mylan Feud

Buying Allergan Plc’s generic-drug business would give Teva Pharmaceutical Industries Ltd. Chief Executive Officer Erez Vigodman a graceful exit from his four-month long pursuit of rival Mylan NV -- just as that takeover’s prospects become dimmest.

Teva is likely to announce as early as Monday that it will buy the Allergan unit for about $40.5 billion, people familiar with the matter said. Teva’s shares were suspended from trading in Tel Aviv on Monday pending a “significant” announcement. The Israeli drugmaker will also withdraw its $40.1 billion hostile offer to acquire Mylan, the people said, asking not to be identified because the information is confidential.